Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre

References

• Huang C, Wang Y, Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Hassan SA, Sheikh FN. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. doi:10.7759/cureus.7355
   PubMed Web of Science ®Google Scholar
• Darif D, Hammi I, Kihel A. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog. 2021;153:104799. doi:10.1016/j.micpath.2021.104799
   PubMed Web of Science ®Google Scholar
• Azimirad M, Noori M, Raeisi H, et al. How does COVID-19 pandemic impact on incidence of Clostridioides difficile infection and exacerbation of its gastrointestinal symptoms? Front Med. 2021;13(8):775063. doi:10.3389/fmed.2021.775063
   Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Contou D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020;10:119–120. doi:10.1186/s13613-020-00736-x
   PubMed Web of Science ®Google Scholar
• Shafran N, Shafran I, Ben-Zvi H, et al. Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Sci Rep. 2021;11:12703. doi:10.1038/s41598-021-92220-0
   PubMed Web of Science ®Google Scholar
• Zhu X, Ge Y, Wu T, et al. 2020. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020;285:198–199. doi:10.1016/j.virusres.2020.198005
   Web of Science ®Google Scholar
• Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020;201:1380–1388. doi:10.1164/rccm.202002-0445OC
   PubMed Web of Science ®Google Scholar
• Bentivegna E, Luciani M, Arcari L, Santino I, Simmaco M, Martelletti P. Reduction of multidrug-resistant (MDR) bacterial infections during the COVID-19 pandemic: a retrospective study. Int J Environ Res Public Health. 2021;18(3):1003. doi:10.3390/ijerph18031003
   Web of Science ®Google Scholar
• De Bruyn A, Verellen S, Bruckers L, et al. Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. BMC Infect Dis. 2022;22(1):207. doi:10.1186/s12879-022-07192-x
   Web of Science ®Google Scholar
• Vaillancourt M, Jorth P. The unrecognized threat of secondary bacterial infections with COVID-19. mBio. 2020;11(4):4–5. doi:10.1128/mBio.01806-20
   Web of Science ®Google Scholar
• Pourajam S, Kalantari E, Talebzadeh H, et al. Secondary bacterial infection and clinical characteristics in patients with COVID-19 admitted to two intensive care units of an academic hospital in Iran during the first wave of the pandemic. Front Cell Infect Microbiol. 2022;23(12):784130. doi:10.3389/fcimb.2022.784130
   Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31 ed. Wayne PA: Clinical and Laboratory Standard Institute; 2021.
   Google Scholar
• Vijay S, Bansal N, Rao BK, et al. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infect Drug Resist. 2021;14:1893–1903. doi:10.2147/IDR.S299774
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang Y, Wu J. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Em Microbes Infections. 2020;9(1):1958–1964. doi:10.1080/22221751.2020.1812437
   PubMed Web of Science ®Google Scholar
• Shafran N, Shafran I, Ben-Zvi H, et al. Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Sci Rep. 2021;11(1):127–128.
   Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Shoaib N, Noureen N, Munir R, et al. COVID-19 severity: studying the clinical and demographic risk factors for adverse outcomes. PLoS One. 2021;16(8):e0255999. doi:10.1371/journal.pone.0255999
   PubMed Web of Science ®Google Scholar
• Neves M, de Matos L, Vasques A, et al. COVID-19 and aging: identifying measures of severity. SAGE Open Med. 2021;9:205031212110274. doi:10.1177/20503121211027462
   Web of Science ®Google Scholar
• Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317. doi:10.1038/s41467-020-19741-6
   PubMed Web of Science ®Google Scholar
• Thevarajan I, Buising KL. Benjamin C Cowie.Clinical presentation and management of COVID‐19. Med J Aust. 2020;213(3):134–139. doi:10.5694/mja2.50698
   Web of Science ®Google Scholar
• O’Toole R. The interface between COVID-19 and bacterial healthcare-associated infections. Clin Microbiol Infect. 2021;27(12):1772–1776. doi:10.1016/j.cmi.2021.06.001
   Web of Science ®Google Scholar
• Palanisamy N, Vihari N, Meena D, et al. Clinical profile of bloodstream infections in COVID-19 patients: a retrospective cohort study. BMC Infect Dis. 2021;21(1). doi:10.1186/s12879-021-06647-x
   Web of Science ®Google Scholar
• Gragueb-Chatti I, Lopez A, Hamidi D, et al. Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study. Ann Intensive Care. 2021;11(87). doi:10.1186/s13613-021-00876-8
   Web of Science ®Google Scholar
• Waterer G, Pickens C, Wunderink R. Antibiotic‐resistant bacteria: COVID ‐19 hasn’t made the challenge go away. Respirology. 2021;26(11):1024–1026. doi:10.1111/resp.14166
   Web of Science ®Google Scholar
• Brzozowski K. Mucormycosis and COVID-19 in the United States: a real-world evidence analysis of risk factors and survival among patients with mucormycosis, with and without COVID-19 preceding the infection. Open Forum Infectious Dis. 2021;8(Supplement_1):S72–S73. doi:10.1093/ofid/ofab466.121
   Google Scholar
• Lai C, Yu W. COVID-19 associated with pulmonary aspergillosis: a literature review. J Microbiol Immunol Infection. 2021;54(1):46–53. doi:10.1016/j.jmii.2020.09.004
   Web of Science ®Google Scholar
• Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). J Infect Public Health. 2021;13(1):5–6.
   Google Scholar
• Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8(1). doi:10.1186/s40560-020-00466-z
   Web of Science ®Google Scholar
• Jindal R, Gupta M, Khan F, Chaudhry G. Prevalence of co-morbidities and its association with mortality in Indian patients with COVID-19: a meta-analysis. Indian J Anaesth. 2022;66(6):399. doi:10.4103/ija.ija_845_21
   Web of Science ®Google Scholar
• Huang I, Lim M, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome. Clin Res Rev. 2020;14(4):395–403.
   Google Scholar
• Vaillancourt M, Jorth P. The unrecognized threat of secondary bacterial infections with COVID-19. mBio. 2020;11(4):215.
   Web of Science ®Google Scholar
• Nag V, Kaur N. Superinfections in COVID-19 patients: role of antimicrobials. Dubai Med J. 2021;4(2):117–126. doi:10.1159/000515067
   Google Scholar